56 related articles for article (PubMed ID: 30043639)
21. Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research.
Chira S; Nutu A; Isacescu E; Bica C; Pop L; Ciocan C; Berindan-Neagoe I
Cells; 2022 Sep; 11(18):. PubMed ID: 36139356
[TBL] [Abstract][Full Text] [Related]
22. FOXA1: a transcription factor with parallel functions in development and cancer.
Bernardo GM; Keri RA
Biosci Rep; 2012 Apr; 32(2):113-30. PubMed ID: 22115363
[TBL] [Abstract][Full Text] [Related]
23. FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.
Albayrak G; Konac E; Ugras Dikmen A; Bilen CY
Exp Biol Med (Maywood); 2018 Aug; 243(12):990-994. PubMed ID: 30043639
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
25. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
[TBL] [Abstract][Full Text] [Related]
26. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
27. SRJ23, a new semisynthetic andrographolide derivative: in vitro growth inhibition and mechanisms of cell cycle arrest and apoptosis in prostate cancer cells.
Wong HC; Wong CC; Sagineedu SR; Loke SC; Lajis NH; Stanslas J
Cell Biol Toxicol; 2014 Oct; 30(5):269-88. PubMed ID: 25070834
[TBL] [Abstract][Full Text] [Related]
28. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
29. Immunoblot screening of CRISPR/Cas9-mediated gene knockouts without selection.
Estep JA; Sternburg EL; Sanchez GA; Karginov FV
BMC Mol Biol; 2016 Apr; 17():9. PubMed ID: 27038923
[TBL] [Abstract][Full Text] [Related]
30. Resources for the design of CRISPR gene editing experiments.
Graham DB; Root DE
Genome Biol; 2015 Nov; 16():260. PubMed ID: 26612492
[TBL] [Abstract][Full Text] [Related]
31. The Molecular Taxonomy of Primary Prostate Cancer.
Cancer Genome Atlas Research Network
Cell; 2015 Nov; 163(4):1011-25. PubMed ID: 26544944
[TBL] [Abstract][Full Text] [Related]
32. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer.
Yang YA; Yu J
Genes Dis; 2015 Jun; 2(2):144-151. PubMed ID: 26114156
[TBL] [Abstract][Full Text] [Related]
33. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
Jin HJ; Zhao JC; Wu L; Kim J; Yu J
Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
[TBL] [Abstract][Full Text] [Related]
34. FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.
DeGraff DJ; Grabowska MM; Case TC; Yu X; Herrick MK; Hayward WJ; Strand DW; Cates JM; Hayward SW; Gao N; Walter MA; Buttyan R; Yi Y; Kaestner KH; Matusik RJ
Lab Invest; 2014 Jul; 94(7):726-39. PubMed ID: 24840332
[TBL] [Abstract][Full Text] [Related]
35. Genome engineering using the CRISPR-Cas9 system.
Ran FA; Hsu PD; Wright J; Agarwala V; Scott DA; Zhang F
Nat Protoc; 2013 Nov; 8(11):2281-2308. PubMed ID: 24157548
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]